---
title: Nerve Conduction Velocity in Diabetic Children
nct_id: NCT01017718
overall_status: COMPLETED
sponsor: Landeskrankenhaus Feldkirch
study_type: OBSERVATIONAL
primary_condition: Type 1 Diabetes Mellitus
countries: Austria
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01017718.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01017718"
ct_last_update_post_date: 2011-09-27
last_seen_at: "2026-05-12T06:05:30.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Nerve Conduction Velocity in Diabetic Children

**Official Title:** Prevalence of Pathological Nerve Conduction Velocity in Children and Adolescents Suffering From Diabetes Mellitus Type I

**NCT ID:** [NCT01017718](https://clinicaltrials.gov/study/NCT01017718)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 40
- **Lead Sponsor:** Landeskrankenhaus Feldkirch
- **Conditions:** Type 1 Diabetes Mellitus
- **Start Date:** 2009-05
- **Completion Date:** 2011-07
- **CT.gov Last Update:** 2011-09-27

## Brief Summary

The investigators intend to study children and adolescents from 8 to 18 years suffering from diabetes mellitus type 1 for more than one year. The patients will undergo a detailed clinical examination for anthropometric data, blood pressure, blood and urine. Motor and sensory nerve conduction velocity will be examined by electrical stimulation using surface patch electrodes. The nerves to be examined are the nervus tibialis anterior, nervus medianus and nervus peroneus.

Primary outcome:

How many children and adolescents suffering from diabetes mellitus type 1 (duration of disease \> 1 year, age 8 to 18a, insulin requirement \> 0.5 IU/kg/d) show pathological nerve conduction velocity?

Secondary outcome:

Is there a significant difference in nerve conduction velocity between the group of diabetic patients and the control group of healthy young people? Does the quality of disease control have an influence on nerve conduction velocity? Is there a correlation between nerve conduction velocity in our study patients and the Young Score? Is there a correlation between pathological nerve conduction velocity and other long-term vascular complications (nephropathy, retinopathy)?

## Detailed Description

Diabetes mellitus type 1 is a chronic disease in which the pancreas no longer produces enough insulin and the glucose in the blood cannot be absorbed into the cells of the body. The main symptom is hyperglycemia. After 10 to 15 years of disease long-term vascular complications including retinopathy, nephropathy, neuropathy, and macrovascular disease are seen. Among the most common long-term complications of diabetes, diabetic neuropathy (DN) is a significant source of morbidity and mortality. There is considerable uncertainty about the prevalence of DN due to a lack of large epidemiological studies and consensus on diagnostic criteria with data variation ranging from 5% to 100%. DN is thought to result from diabetic microvascular injury involving small blood vessels that supply nerves (vasa nervorum). It is a set of heterogeneous clinical syndromes that affect distinct regions of the nervous system, individually or combined. The investigators differentiate autonomic and peripheral neuropathy: Clinical presentation of autonomic neuropathy includes postural hypotension, vomiting, diarrhea, bladder paresis, impotence, sweating abnormalities, and gastric fullness. Peripheral neuropathy presents as altered pain sensations (dys-, para-, hypo- or hyperesthesia), burning, and either superficial or deep pain. The examination of choice for the diagnosis of peripheral neuropathy is to determine nerve conduction velocity.

One of the main goals in treating children and adolescents suffering from diabetes mellitus type I is to avoid long-term complications by early detection of clinical or, even better, subclinical signs. For this reason, the International Society for Pediatric and Adolescent Diabetes (ISPAD) periodically issues Clinical Practice Consensus Guidelines, particularly for screening for vascular complications. With regard to DN there is still uncertainty about the time frame, intensity and diagnostic method of choice.

The investigators aim to examine children and adolescents from 8 to 18 years suffering from diabetes mellitus type I for more than one year with an insulin requirement of more than 0.5 IU/kg/d. The investigators will exclude children with other chronic diseases, handicapped children or children suffering from cancer or chronic renal impairment, as well as children with other neurological diseases which can also cause a change in nerve conduction velocity, and children with blood glucose levels below 50 or above 350 mg/dl. At the time of the annual check-up the patients will undergo a detailed examination for anthropometric data, blood pressure, blood and urine. Thereafter, motor and sensory nerve conduction velocity will be determined by electrical stimulation using surface patch electrodes. The nerves to be investigated are the nervus tibialis anterior, nervus medianus and nervus peroneus. Finally, the patient will undergo a neurological investigation to calculate his Young Score (Neuropathy Symptom Score).

## Eligibility

- **Minimum age:** 8 Years
- **Maximum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Children and adolescents with diabetes mellitus type 1 (duration of disease \> 1 year, age 8 to 18a, insulin requirement \> 0.5 IU/kg/d)

Exclusion Criteria:

* No consent
* Diabetic children with duration of diabetes \< 1 year, age \<8 or \>18 year or insulin requirement \> 0.5 IU/kg/d
* Blood glucose levels \<50 or \>350 mg/dl
* Children with chronic diseases, handicapped children, children with cancer, chronic renal impairment, or neurological diseases
```

## Primary Outcomes

- **How many children and adolescents suffering from diabetes mellitus type 1 (duration of disease > 1 year, age 8 to 18a, insulin requirement > 0.5 IU/kg/d) show pathological nerve conduction velocity?** _(time frame: One electrophysiological investigation (nerve conduction velocity))_

## Secondary Outcomes

- **Is there a correlation between nerve conduction velocity in our study patients and the Young Score?** _(time frame: One clinical investigation (Young score))_

## Locations (1)

- Department of Pediatrics, University Teaching Hospital, Landeskrankenhaus Feldkirch, Feldkirch, Austria

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.department of pediatrics, university teaching hospital, landeskrankenhaus feldkirch|feldkirch||austria` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01017718.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01017718*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*